Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q0OD
|
||||
| Former ID |
DNCL001580
|
||||
| Drug Name |
Secukinumab
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Severe plaque psoriasis [ICD10:L40] | Approved | [556264] | ||
| Psoriatic arthritis; Rheumatoid arthritis [ICD9: 696, 710-719, 714; ICD10:L40.5, M07, M05-M06] | Phase 4 | [525316], [542955], [551965] | |||
| Rheumatoid arthritis; Dry eye; Multiple sclerosis; Psoriatic arthritis; Type 1 diabetes mellitus; Alopecia areata; Atopic dermatitis [ICD10:E10, G35, H19.3, L20, L40, L40.5, M07, M05-M06] | Phase 2 | [889360], [889365], [889369], [889386], [889389], [889416], [889418], [889424], [889431], [889437] | |||
| Company |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
||||
| SuperDrug ATC ID |
L04AC10
|
||||
| References | |||||
| Ref 525316 | ClinicalTrials.gov (NCT02547714) Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A. | ||||
| Ref 542955 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8078). | ||||
| Ref 551965 | Clinical pipeline report, company report or official report of Novartis. | ||||
| Ref 556264 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| Ref 889360 | ClinicalTrials.gov (NCT01250171) The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients | ||||
| Ref 889365 | ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate | ||||
| Ref 889369 | ClinicalTrials.gov (NCT01426789) A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients | ||||
| Ref 889386 | ClinicalTrials.gov (NCT01874340) Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis | ||||
| Ref 889389 | ClinicalTrials.gov (NCT02044848) Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus | ||||
| Ref 889416 | ClinicalTrials.gov (NCT02594098) Secukinumab for Treatment of Atopic Dermatitis | ||||
| Ref 889418 | ClinicalTrials.gov (NCT02599129) A Study of Secukinumab for the Treatment of Alopecia Areata | ||||
| Ref 889424 | ClinicalTrials.gov (NCT02854163) Effect of Secukinumab in the Treatment of Psoriatic Arthritis | ||||
| Ref 889431 | ClinicalTrials.gov (NCT03041038) The Efficacy and Safety of Secukinumab in Patients With Ichthyoses | ||||
| Ref 889437 | ClinicalTrials.gov (NCT03131570) Safety and Efficacy of Secukinumab in Mild Psoriasis | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.